[Pharmacokinetic validation of the antitumor efficacy of aclarubicin administered by various routes in CBF1 mice with Ca 755 carcinoma].
Aclarubicin was established to be more active against murine mammary gland carcinoma Ca 755 after its intravenous injection as compared to oral administration. Pharmacokinetics of aclarubicin and its biologically active metabolites MA 144 N1, MA 144 T1 and MA 144 M1 was studied by HPLC in the tumour tissues. Not only quantitative but also qualitative differences in the ratios of the unchanged antibiotic and its metabolites in tumour Ca 755 were detected after aclarubicin administration by these methods. Diverse therapeutic activity was shown to be due to these differences.
M M
MM
Viadro
A A
AA
Firsov
T G
TG
Terent'eva
L B
LB
Kashina
D015250:Aclarubicin / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000818:Animals; D002277:Carcinoma / Q000032:analysis / Q000188:drug therapy / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004353:Drug Evaluation, Preclinical; D005260:Female; D007275:Injections, Intravenous; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D013997:Time Factors
D015250:Aclarubicin
Farmakokineticheskoe obosnovanie protivoopukholevoĭéffektivnosti aklarubitsina pri razlichnykh sposobakh primeneniia u mysheĭ linii CBF1 s kartsinomoĭ Ca 775.